FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
INFUGEM
gemcitabine hydrochloride
Peak
Fosun Pharma
INTRAVENOUS · SOLUTION
2018
NDA
0/100
INGREZZA
valbenazine
Peak
ORAL · CAPSULE
2017
NDA
0/100
INLYTA
axitinib
Peak
Pfizer
ORAL · TABLET
2012
SMNDA
0/100
INOMAX
nitric oxide
Peak
INHALATION · GAS
oxygenationreduce the need for extracorporeal membrane oxygenation in term+4
1999
NDA
0/100
INQOVI
cedazuridine and decitabine
Peak
Taiho Oncology
ORAL · TABLET
2020
NDA
0/100
INREBIC
fedratinib hydrochloride
Peak
Bristol Myers Squibb
ORAL · CAPSULE
high-risk primarysecondary (post-polycythemia vera+1
2019
NDA
0/100
INTRAROSA
prasterone
Peak
Millicent Pharma
VAGINAL · INSERT
moderate to severe dyspareuniaa symptom of vulvar+2
2016
NDA
0/100
INVEGA HAFYERA
paliperidone palmitate
Peak
Johnson & Johnson
INTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE
schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (eschizophrenia
2015
NDA
0/100
INVEGA TRINZA
paliperidone palmitate
Peak
Johnson & Johnson
INTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE
schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (eschizophrenia
2015
NDA
0/100
INVELTYS
loteprednol etabonate
Peak
Alcon
OPHTHALMIC · SUSPENSION/DROPS
post-operative inflammationpain following ocular surgery
2018
NDA
0/100
IONSYS
fentanyl hydrochloride
Peak
Novartis
IONTOPHORESIS, TRANSDERMAL · SYSTEM
2006
NDA
0/100
ISENTRESS
raltegravir
Peak
Merck & Co.
ORAL · TABLET
combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients ()combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg ()+4
2007
SMNDA
0/100
ISENTRESS HD
raltegravir
Peak
Merck & Co.
ORAL · TABLET
combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients ()combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg ()+4
2007
SMNDA
0/100
ISTURISA
osilodrostat
Peak
Recordati
ORAL · TABLET
endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option
2020
SMNDA
0/100
IYUZEH
latanoprost ophthalmic solution 0.005%
Peak
Thea Pharma
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
2022
NDA
0/100
JADENU
deferasirox
Peak
Novartis
ORAL · TABLET
2015
NDA
0/100
JARDIANCE
empagliflozin
Peak
Boehringer Ingelheim
ORAL · TABLET
2014
SMNDA
0/100
JATENZO
testosterone undecanoate
Peak
Tolmar
ORAL · CAPSULE
2019
NDA
0/100
JAYPIRCA
pirtobrutinib
Peak
Eli Lilly and Company
ORAL · TABLET
2023
SMNDA
0/100
JENTADUETO
linagliptin and metformin hydrochloride
Peak
Boehringer Ingelheim
ORAL · TABLET
2012
NDA
0/100
JENTADUETO XR
linagliptin and metformin hydrochloride
Peak
Boehringer Ingelheim
ORAL · TABLET, EXTENDED RELEASE
2016
NDA
0/100
JESDUVROQ
daprodustat
Peak
GSK
ORAL · TABLET
2023
SMNDA
0/100
JEVTANA KIT
cabazitaxel
Peak
Sanofi
INTRAVENOUS · SOLUTION
combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimenprostate cancer
2010
NDA
0/100
JOENJA
leniolisib
Peak
Pharming Group
ORAL · TABLET
activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adultolder
2023
SMNDA
0/100
← PreviousPage 36 of 55Next →